$LXRX I listened for a second time the Stifel webcast and got to think of three things: 1) publishing 2 articles in the NEJM is no small feat. This journal is in the top three scientific journals for the Impact metric, along with Nature and The Lancet. It sure brings attention and praise to your work, but we we will see if it translate in real value. 2) when you have to write such an article, the peer reviewing process can take a while, which means that Lexicon, with their results in hand, surely had plenty of time to knock on the door of a few potential partners. 3)I guess that if they want to submit something to the FDA, they better have a good strong partner, this way they share the risk and they’ll be better positioned to execute supplemental research if th
  • 4